Unjha Formulations Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

Technical Factors Drive Upgrade

The most significant catalyst behind the rating change is the improvement in Unjha Formulations’ technical grade, which moved from bearish to mildly bearish. This shift reflects a nuanced but positive change in market sentiment and price momentum. Key technical indicators reveal a complex picture: the weekly Moving Average Convergence Divergence (MACD) has turned mildly bullish, signalling potential upward momentum in the near term, while the monthly MACD remains bearish, indicating longer-term caution.

Other technical metrics show a mixed but cautiously optimistic outlook. The weekly Know Sure Thing (KST) indicator is mildly bullish, supporting the short-term positive trend, whereas the monthly KST remains bearish. Relative Strength Index (RSI) readings on both weekly and monthly charts show no clear signals, suggesting the stock is neither overbought nor oversold. Bollinger Bands indicate sideways movement weekly but mildly bearish conditions monthly, while daily moving averages remain mildly bearish. The Dow Theory analysis shows no clear weekly trend but a mildly bearish monthly trend.

Overall, these technical nuances have contributed to a more constructive short-term outlook, justifying the upgrade from Strong Sell to Sell. The stock’s price has responded accordingly, rising 5.47% on the day to close at ₹20.25, up from the previous close of ₹19.20. This price movement contrasts with the broader market, where the Sensex has shown more modest returns over comparable periods.

Quality Assessment Remains Weak

Despite the technical improvement, Unjha Formulations continues to exhibit weak quality metrics. The company reported flat financial performance in the fourth quarter of FY25-26, with operating losses persisting. The quarterly PBDIT stood at a negative ₹0.45 crore, while PBT excluding other income was also negative at ₹0.49 crore. Earnings per share (EPS) for the quarter hit a low of ₹-1.65, underscoring ongoing profitability challenges.

Long-term fundamental strength remains weak, as evidenced by the company’s poor ability to service debt. The average EBIT to interest ratio is a mere 0.49, indicating that operating earnings are insufficient to cover interest expenses comfortably. This financial strain is a critical factor weighing on the company’s quality grade and investor confidence.

Valuation Presents a Mixed Picture

On the valuation front, Unjha Formulations offers some attractive features despite its operational difficulties. The company’s return on equity (ROE) stands at a robust 18.5%, signalling efficient use of shareholder capital. Moreover, the stock trades at a price-to-book (P/B) ratio of 2.4, which is considered very attractive relative to its peers and historical averages. This valuation discount could appeal to value-oriented investors looking for potential turnaround opportunities.

However, the stock’s price performance over the past year has been disappointing, with a return of -13.76%, underperforming the broader BSE500 index’s negative return of -3.18%. Despite this, profits have risen by 31% over the same period, resulting in a low PEG ratio of 0.2, which suggests the stock may be undervalued relative to its earnings growth potential.

Financial Trend Remains Flat

Financial trends for Unjha Formulations remain largely flat, with no significant improvement in quarterly results. The company’s operating losses and weak profitability metrics continue to weigh on its financial trajectory. This stagnation contrasts with the stock’s longer-term performance, which has been more favourable. Over three and five years, the stock has generated returns of 68.75% and 84.59%, respectively, outperforming the Sensex’s 17.19% and 45.53% returns over the same periods. However, the 10-year return of 161.97% trails the Sensex’s 182.02%, indicating mixed long-term performance.

Shareholding and Market Capitalisation

Unjha Formulations is classified as a micro-cap stock, with a market capitalisation reflecting its relatively small size in the pharmaceutical sector. The majority of its shares are held by non-institutional investors, which can contribute to higher volatility and less predictable trading patterns. This ownership structure may also impact liquidity and investor interest.

Comparative Returns Highlight Volatility

Examining Unjha Formulations’ returns relative to the Sensex reveals a volatile performance profile. The stock outperformed the Sensex over the past week with a 6.64% gain compared to the index’s -0.54%. However, over one month, the stock’s 1.25% return lagged behind the Sensex’s 4.05%. Year-to-date and one-year returns show significant underperformance, with the stock down 19.00% and 13.76%, respectively, versus the Sensex’s declines of 10.23% and 8.61%. These fluctuations underscore the stock’s sensitivity to market conditions and company-specific developments.

Outlook and Investment Implications

While the upgrade from Strong Sell to Sell reflects a modest improvement in technical indicators, investors should remain cautious given the company’s weak financial fundamentals and flat earnings trend. The attractive valuation metrics and improving technical signals may offer some upside potential, but the persistent operating losses and poor debt servicing capacity present significant risks.

Investors considering Unjha Formulations should weigh the short-term technical optimism against the longer-term fundamental challenges. The stock’s micro-cap status and non-institutional majority ownership add layers of volatility and liquidity risk. As such, a Sell rating remains appropriate, signalling that while the stock is no longer a strong sell, it is not yet a compelling buy.

Summary of Ratings and Scores

As of 8 July 2026, Unjha Formulations holds a Mojo Score of 31.0 with a Mojo Grade of Sell, upgraded from Strong Sell. The company remains classified as a micro-cap within the Pharmaceuticals & Biotechnology sector. Technical grades have improved from bearish to mildly bearish, while quality and financial trend assessments remain weak. Valuation is rated as very attractive, supported by a strong ROE and low PEG ratio. This comprehensive evaluation by MarketsMOJO reflects a nuanced investment stance balancing technical recovery against fundamental headwinds.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today